ProShare Advisors
EDIT icon

ProShare Advisors’s Editas Medicine EDIT Stock Holding History

ProShare Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.8K Sell
18,137
-496
-3% -$1.45K ﹤0.01% 1831
2026
Q1 		$46K Sell
18,633
-2,161
-10% -$4.57K ﹤0.01% 1795
2025
Q4 		$42.6K Buy
20,794
+3,161
+18% +$9.13K ﹤0.01% 1972
2025
Q3 		$61.2K Sell
17,633
-2,799
-14% -$7.81K ﹤0.01% 1911
2025
Q2 		$45K Sell
20,432
-1,234
-6% -$2.02K ﹤0.01% 2003
2025
Q1 		$25.1K Sell
21,666
-5,586
-20% -$8.22K ﹤0.01% 2021
2024
Q4 		$34.6K Buy
27,252
+6,718
+33% +$17.1K ﹤0.01% 2227
2024
Q3 		$70K Buy
20,534
+4,439
+28% +$19.3K ﹤0.01% 1935
2024
Q2 		$75.2K Sell
16,095
-4,420
-22% -$24.9K ﹤0.01% 1698
2024
Q1 		$152K Buy
20,515
+1,681
+9% +$14K ﹤0.01% 1740
2023
Q4 		$191K Buy
18,834
+2,811
+18% +$24.7K ﹤0.01% 1650
2023
Q3 		$125K Buy
16,023
+2,504
+19% +$21.5K ﹤0.01% 1591
2023
Q2 		$111K Buy
13,519
+606
+5% +$5.28K ﹤0.01% 1681
2023
Q1 		$93.6K Sell
12,913
-1,664
-11% -$14.8K ﹤0.01% 1602
2022
Q4 		$129K Buy
14,577
+1,180
+9% +$13K ﹤0.01% 1597
2022
Q3 		$164K Buy
13,397
+291
+2% +$4.53K ﹤0.01% 1451
2022
Q2 		$154K Sell
13,106
-6,807
-34% -$91.2K ﹤0.01% 1536
2022
Q1 		$379K Sell
19,913
-4,662
-19% -$86.7K ﹤0.01% 1472
2021
Q4 		$653K Buy
24,575
+1,228
+5% +$42.3K ﹤0.01% 1284
2021
Q3 		$959K Sell
23,347
-6,583
-22% -$361K ﹤0.01% 925
2021
Q2 		$1.7M Buy
29,930
+2,780
+10% +$103K 0.01% 779
2021
Q1 		$1.14M Buy
27,150
+3,613
+15% +$206K ﹤0.01% 912
2020
Q4 		$1.65M Buy
23,537
+5,804
+33% +$238K 0.01% 695
2020
Q3 		$498K Buy
17,733
+1,407
+9% +$45.8K ﹤0.01% 949
2020
Q2 		$483K Buy
16,326
+6,240
+62% +$163K ﹤0.01% 962
2020
Q1 		$200K Sell
10,086
-8,019
-44% -$202K ﹤0.01% 1013
2019
Q4 		$536K Sell
18,105
-952
-5% -$23.8K ﹤0.01% 1031
2019
Q3 		$433K Sell
19,057
-210
-1% -$5.2K ﹤0.01% 1029
2019
Q2 		$477K Sell
19,267
-2,000
-9% -$47.7K ﹤0.01% 1036
2019
Q1 		$520K Buy
21,267
+224
+1% +$5.07K ﹤0.01% 1006
2018
Q4 		$479K Sell
21,043
-3,984
-16% -$108K ﹤0.01% 968
2018
Q3 		$796K Sell
25,027
-823
-3% -$26.6K 0.01% 917
2018
Q2 		$926K Sell
25,850
-555
-2% -$19.7K 0.01% 858
2018
Q1 		$875K Sell
26,405
-1,398
-5% -$49.8K 0.01% 876
2017
Q4 		$854K Buy
27,803
+2,036
+8% +$51.3K 0.01% 896
2017
Q3 		$619K Buy
25,767
+1,556
+6% +$29.6K 0.01% 885
2017
Q2 		$406K Buy
24,211
+3,857
+19% +$69.5K ﹤0.01% 1028
2017
Q1 		$454K Sell
20,354
-4,966
-20% -$103K ﹤0.01% 1035
2016
Q4 		$411K Buy
+25,320
New +$384K ﹤0.01% 1180

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

ProShare Advisors's EDIT Position: Q2 2026 in Review

ProShare Advisors reduced its Editas Medicine (EDIT) stake by 2.7% in Q2 2026, selling an estimated $1.45K and leaving 18,137 shares worth $58.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

ProShare Advisors first reported a position in EDIT in Q4 2016 and has held it in 39 quarters since. The position peaked at $1.7M in Q2 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • ProShare Advisors held 18,137 shares of Editas Medicine worth $58.8K as of Q2 2026.
  • ProShare Advisors sold 496 Editas Medicine shares in Q2 2026, an estimated $1.45K.
  • Editas Medicine made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1831 holding.
  • ProShare Advisors first reported a position in Editas Medicine in Q4 2016 and has held it in 39 quarters since.
  • ProShare Advisors's Editas Medicine position peaked at $1.7M in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.